New Medication Offers First Comprehensive Treatment for Narcolepsy Type 1

The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets, marking a significant advancement in the treatment of narcolepsy type 1. According to the FDA, this new medication is the first to be approved for the full spectrum of symptoms associated with this chronic neuropsychiatric disorder and the first to directly address the underlying biological cause by restoring orexin signaling in the brain.

Narcolepsy type 1 affects an estimated one in every 2,000 individuals in the United States and is characterized by the loss of brain cells responsible for producing orexin, a vital chemical messenger that regulates wakefulness and sleep. This deficiency leads to a range of debilitating symptoms, including excessive daytime sleepiness, cataplexy (sudden muscle weakness triggered by emotions), sleep paralysis, and disrupted nighttime sleep. Until now, treatments for narcolepsy type 1 have primarily focused on managing individual symptoms rather than addressing the root cause.

Orzeyful works by directly stimulating the brain receptors that orexin would normally activate, thereby replenishing the missing signal. Administered as an oral tablet taken twice daily, the drug offers a new therapeutic approach by targeting the fundamental biological mechanism of the disease. This contrasts with previous treatments that often relied on stimulants or sedatives to mask symptoms.

The efficacy and safety of Orzeyful were rigorously evaluated in two clinical trials involving 273 adults diagnosed with narcolepsy type 1. These studies demonstrated that patients treated with Orzeyful experienced notable improvements in their ability to remain awake during the day, alongside a significant reduction in excessive daytime sleepiness and cataplexy episodes. Participants also reported overall improvement across the complete range of narcolepsy symptoms, including sleep paralysis and hallucinations. The drug is approved for adults and its safety and effectiveness in individuals under 18 years of age have not yet been determined.

Common side effects associated with Orzeyful include insomnia, increased urinary frequency, urgency to urinate, and increased saliva production. The rate at which participants discontinued the medication due to side effects was low. Patients are advised to discuss all current medications with their healthcare providers, as Orzeyful should not be taken concurrently with strong CYP3A inhibitors. Additionally, Orzeyful has been recommended for scheduling under the Controlled Substances Act, with lawful marketing contingent on a decision from the Drug Enforcement Agency.

The development of Orzeyful was supported by the FDA’s Breakthrough Therapy Designation and Priority Review designations. Breakthrough Therapy Designation is awarded to drugs showing substantial early clinical evidence of significant improvement over existing treatments for serious conditions, fostering closer collaboration and guidance during the development process. Priority Review expedites the FDA’s review timeline for drugs that offer substantial advancements in treating serious conditions. Takeda Pharmaceuticals America, Inc. received the approval for Orzeyful.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration.

Video Spotlight